Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis

Brian J Anderson1, Gerard Pons, Elisabeth Autret-Leca

  • 1Department of Anaesthesiology, University of Auckland, Auckland, New Zealand. briana@adhb.govt.nz

Paediatric Anaesthesia
|March 25, 2005
PubMed

Insights

This study analyzed propacetamol pharmacokinetics in children, finding that standard dosing achieves effective paracetamol concentrations for pain relief. Dosing adjustments may be needed for children under one year due to reduced clearance.

Area of Science:

  • Pharmacokinetics
  • Pediatric Pharmacology
  • Pain Management

Background:

  • Understanding propacetamol pharmacokinetics in children is crucial for optimizing pain management.
  • Standard dosing regimens require evaluation to ensure therapeutic efficacy.

Purpose of the Study:

  • To describe propacetamol pharmacokinetics in pediatric populations.
  • To predict paracetamol concentrations following standard propacetamol dosing.
  • To assess the relative bioavailability of intravenous propacetamol compared to oral administration.

Main Methods:

  • Population pharmacokinetic analysis using nonlinear mixed effects models (NONMEM).
  • Inclusion of time-concentration data from 144 children receiving intravenous propacetamol and 86 children receiving oral paracetamol elixir.
  • Utilized data from seven separate studies.

Main Results:

  • A three-compartment linear disposition model best described the data.
  • Clearance increased with age, reaching mature values by one year.
  • Peripheral volume of distribution decreased with age, stabilizing by six months.
  • Relative bioavailability of IV propacetamol was 0.5 compared to oral elixir.

Conclusions:

  • Standard propacetamol dosing (30 mg/kg every 6 hours) achieves a mean paracetamol concentration of 10 mg/L in children aged 2-15 years.
  • This concentration provides satisfactory analgesia for mild to moderate pain.
  • Reduced clearance in children under one year necessitates dose scaling for target concentrations.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...